KEEPsAKE 2 results: RZB showed greater improvements in signs & symptoms of PsA vs PBO, met all primary/secondary endpoints, & was well tolerated in Bio-IR or csDMARD-IR pts. Safety profile consistent w/ PsO trials. Abstract #OP0228 #EULAR2021 @RheumNow https://t.co/jsF2JVTupg https://t.co/oiZWZ7Pkf2